Adipotide

Key Benefits#

• Targeted reduction of white adipose tissue
• Promotes fat vasculature apoptosis without systemic toxicity
• Demonstrated significant fat loss in primate studies
• Potential for visceral and subcutaneous fat reduction
• Novel non-hormonal mechanism distinct from GLP-1 agonists
• Explored for obesity and metabolic syndrome

Mechanism of Action#

Adipotide consists of a targeting sequence (CKGGRAKDC) that binds prohibitin on white adipose tissue vasculature, linked to a proapoptotic sequence (KLAKLAKKLAKLAK, also known as D(KLAKLAK)2). The targeting sequence homes to fat vasculature, and the proapoptotic sequence disrupts mitochondrial membranes in those endothelial cells, triggering programmed cell death. This selectively cuts off blood supply to adipose tissue, causing fat cell death without affecting other tissues.

Dosing Protocols#

Side Effects#

• Renal toxicity observed in primate studies (transient, dose-dependent)
• Dehydration and electrolyte imbalances in research
• Weight regain upon cessation
• Limited human data; side effect profile largely from animal studies

Contraindications#

No approved human use; research compound onlyRenal impairment (renal toxicity observed in studies)Pregnancy and breastfeeding: contraindicatedNot recommended outside supervised research protocols

Storage#

Lyophilized: store at -20 degrees C. Reconstituted: use within 2 weeks refrigerated at 2-8 degrees C. Protect from light.

1. 1.
   Preclinical efficacy of the GPER-selective agonist G-1 in mouse models of obesity and diabetes

   Sharma G, Hu C, Staquicini DI, Brigman JL, Liu M, Mauvais-Jarvis F et al. · Science translational medicine · 2020PubMed Verified

2. 2.
   Epigenetic Age Acceleration in Adolescence Associates With BMI, Inflammation, and Risk Score for Middle Age Cardiovascular Disease

   Huang RC, Lillycrop KA, Beilin LJ, Godfrey KM, Anderson D, Mori TA et al. · The Journal of clinical endocrinology and metabolism · 2019PubMed Verified

3. 3.
   Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes

   Preiss D, Dawed A, Welsh P, Heggie A, Jones AG, Dekker J et al. · Diabetes, obesity & metabolism · 2017RCTPubMed Verified

4. 4.
   A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication

   Hossen N, Kajimoto K, Akita H, Hyodo M, Harashima H · Journal of controlled release : official journal of the Controlled Release Society · 2013PubMed Verified

5. 5.
   Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium

   Kim DH, Sartor MA, Bain JR, Sandoval D, Stevens RD, Medvedovic M et al. · Diabetes · 2012PubMed Verified

6. 6.
   Comment on "a peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys"

   Criscione L · Science translational medicine · 2012PubMed Verified

7. 7.
   A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys

   Barnhart KF, Christianson DR, Hanley PW, Driessen WH, Bernacky BJ, Baze WB et al. · Science translational medicine · 2011PubMed Verified